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Abstract
Background: Besides being responsible for energy production in the cell, mitochondria are central players in apoptosis as
well as the main source of harmful reactive oxygen species. Therefore, it can be hypothesised that sequence variation in the
mitochondrial genome is a contributing factor to the etiology of diseases related to these different cellular events, including
cancer. The aim of the present study was to assess the frequency of haplogroups and polymorphisms in the control region
(CR) of mitochondrial DNA of peripheral blood mononuclear cells from patients with prostate carcinoma (n=304) versus
patients screened for prostate disease but found to be negative for cancer on biopsy (n=278) in a Middle European
population.
Methodology/Principal Findings: The nine major European haplogroups and the CR polymorphisms were identified by
means of primer extension analysis and DNA sequencing, respectively. We found that mitochondrial haplogroup
frequencies and CR polymorphisms do not differ significantly between patients with or without prostate cancer, implying
no impact of inherited mitochondrial DNA variation on predisposition to prostate carcinoma in a Middle European
population.
Conclusions/Significance: Our results contrast with a recent report claiming an association between mtDNA haplogroup U
and prostate cancer in a North American population of caucasian descent.
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Introduction
Prostate cancer is a major cause of death in the developed
world. It is the most frequent cancer among men in the United
States and the second most common in the European Union [1,2].
A shift in cellular energy production from oxidative phosphor-
ylation in mitochondria to anaerobic glycolysis, called the Warburg
effect, is a fundamental property of cancer cells. Due to the essential
role of enzymes encoded by the mitochondrial DNA (mtDNA) in
energy metabolism, alterations to the mitochondrial genome have
been suspected to be able to cause a metabolic shift in tumors [3].
Furthermore, mitochondrial respiratory activity is associated with
the generation of reactive oxygen species (ROS), which may
contribute to the etiology and progression of cancer [4]. Because
mitochondria play important roles in both ROS production and
apoptosis, the conclusionthat theycould influencethe occurrenceof
cancer is easily drawn.
Most eukaryotic cells contain hundreds of mitochondria which
harbor numerous copies of mtDNA [5,6]. The circular and
double-stranded mitochondrial genome is around 16 kilobase pairs
long and can be further divided into two main regions: the coding
region and the control region. The coding region consists of 37
genes, 24 encoding components of the mitochondrial translational
machinery and 13 genes providing essential subunits of the energy-
generating enzymes of the oxidative phosphorylation (OXPHOS)
pathway [5,7]. The control region (CR), which is non-coding,
contains two hypervariable regions (HVI and HVII) and a
displacement (D-loop) region, and is involved in mtDNA
replication and transcription [8].
The human population has accumulated a high number of
mtDNA base substitutions along radiating maternal lineages, of
which specific combinations constitute the so-called mitochondrial
haplogroups[7,9].NinedistinctEuropeanmtDNAhaplogroups(H,
U, J, T, K, W, I, V, X) were defined by Torroni et al. [10,11].
Although most mitochondrial polymorphisms are believed to be
neutral, population-specific mtDNAs may be functionally different
and exert varying influences on the outcomes of diseases [7,12–14].
Mitochondrial haplogroups and polymorphisms have been
found to be linked with carcinogenesis. For example, the mtDNA
10398A polymorphism is implicated in enhanced ROS production,
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cancer in Indian patients, and for invasive breast cancer in African-
American women [4,15]. In addition, Asian haplogroup D was
found to be associated with a higher risk of developing endometrial
cancer in China [16]. In Caucasian populations, haplogroup K was
associated with a significant increase, and haplogroup U a
significant decrease, in breast cancer risk [17].
Booker et al. [18] reported an elevated frequency of haplogroup
U in prostate carcinoma patients in a study of North American
whites. This Caucasian haplogroup was correlated with a 2-fold
risk of developing the disease [18].
We aimed to replicate the latter study on a Middle European
population. Because associations of age-related diseases have been
demonstrated not only with mitochondrial haplogroups, but also
with single nucleotide polymorphisms (SNPs) in the CR [19], we
also investigated sequence variations in HVI and HVII in our
cohorts.
Results
We assessed the nine major European haplogroups as well as
CR polymorphisms in peripheral blood mononuclear cells of 582
Caucasian males, 304 of whom were diagnosed with prostate
cancer; the remaining 278 were identified with elevated serum
PSA levels but were histologically negative for cancer upon
prostate biopsy and served as the control group. Clinical
characteristics of the cancer patients and controls are shown in
Table 1. All nine European haplogroups were observed in our
cohort. The frequencies of mitochondrial haplogroups did not
differ significantly between the patients with prostate cancer and
the control subjects (Table 2). When mitochondrial haplogroup
frequencies were compared between cancer patients with biopsy
Gleason Score #6 to cancer patients with biopsy Gleason Score
$7 also no significant differences were observed (Table 3).
The mitochondrial CR was sequenced and analyzed between
nucleotide positions 16145 and 530. Two hundred and nineteen
polymorphisms were found among the 582 subjects, with 197
homoplasmic single base-pair exchanges, 10 single base-pair
deletions and 5 single base-pair insertions when compared to the
revised Cambridge Reference Sequence. Two samples presented
the same 6 base-pair deletion of nucleotides 106 to 111. A CA-
deletion at positions 514 and 515 occurred 40 times, and CA-
insertions and CACA-insertions were also found at this site 64
times. CC-insertions occurred at positions 302 and 310, and
heteroplasmy was found in one sample (A 16280 A/G). Of these
219 polymorphisms, 16 are not listed in the MITOMAP or
Human Mitochondrial Genome Database (www.mitomap.org;
www.genpat.uu.se/mtDB/). All polymorphisms and their frequen-
cies in the control and cancer study groups are listed in
Supplementary Table S1.
Two of the 219 polymorphisms - A 189 G, and T 310 C - were
found to have a significantly lower frequency in the cancer patients
compared to the control population (p,0.05) (Table 4, Supple-
mentary Table S1). However, the significance was lost after
correction for multiple comparisons (Bonferroni analysis), leading
to a new required significance level of ,0.00023. Table 4 lists the
35 polymorphisms with a frequency $5% in either the control or
prostate cancer study group.
Table 1. Characteristics of the study populations.
Patients with
prostate carcinoma
Patients with
benign changes
n=304 n=278
Mean (SD
1) age at diagnosis (years) 70.3 (5.4) 66.1 (5.5)
Mean (SD
1) PSA
2 (ng/ml) 24.0 (125.6) 5.4 (4.0)
Prostate volume (g) 35.4 (21.0) 44.3 (33.4)
Biopsy defined as benign 0 100
Mean (SD
1) Gleason Score 6.4 (1.3) -
Gleason Score #6 (%) 55.9 -
Gleason Score $7 (%) 44.1 -
1SD: Standard deviation.
2PSA: Prostate specific antigen.
doi:10.1371/journal.pone.0006370.t001
Table 2. Frequencies (%) of Caucasian mitochondrial
haplogroups in cases and controls.
Haplogroup
Patients with
prostate carcinoma
Patients with
benign changes P-Value
1
n=304 n=278
H 39.1 36.0 0.430
U 16.1 16.9 0.798
J 8.6 9.0 0.851
T 12.8 13.6 0.765
K 7.9 5.4 0.228
W 0.7 1.8 0.267
V 2.0 1.4 0.754
I 1.6 2.9 0.315
X 2.3 1.1 0.344
Others
2 8.9 11.9 0.236
1P-Value: Pearson chi-square or Fisher’s exact test.
2Haplogroups that could not be assigned to one of the nine major European
haplogroups by the SNP combination.
doi:10.1371/journal.pone.0006370.t002
Table 3. Frequencies (%) of Caucasian mitochondrial
haplogroups in prostate carcinoma patients with biopsy
Gleason Score Values #6 and $7.
Haplogroup
Patients with prostate
carcinoma and
Gleason Score #6
Patients with prostate
carcinoma and
Gleason Score $7P - V a l u e
1
n=170 n=134
H 41.8 35.8 0.292
U 15.3 17.2 0.660
J 8.2 9.0 0.824
T 12.4 13.4 0.780
K 7.6 8.2 0.857
W 0.0 1.5 0.193
V 1.2 3.0 0.411
I 1.8 1.5 1.000
X 2.3 2.2 1.000
Others
2 9.4 8.2 0.714
1P-Value: Pearson chi-square or Fisher’s exact test.
2Haplogroups that could not be assigned to one of the nine major European
haplogroups by the SNP combination.
doi:10.1371/journal.pone.0006370.t003
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The aim of the present study was to replicate the survey of
Booker et al. [18], who performed a case-control study on 221
white men with prostate cancer and 246 white controls in North
America and found mitochondrial haplogroup U to be overrep-
resented in the cancer group compared to the control group (OR:
1.95). In Middle European Caucasians we did not find significant
differences between the haplogroup distributions in prostate
cancer patients compared to the controls. Adjustment for multiple
comparisons applied to the study of Booker et al. also led to loss of
statistical significance [18]. The haplogroup distribution of the
North American study closely resembles the distribution in our
cancer patients, whereas the control group in the study of Booker
et al. [18] is underrepresented for haplogroup U by about 45%
compared to our control group (Table 5). When we compared the
American case group to the Austrian control group no significant
association of haplogroups to prostate cancer was detected.
To exclude the possibility that having prostate problems in
general – indicated by elevated PSA serum levels in our patient and
control group - is associated with a higher haplogroup U frequency,
we further assessed the haplogroup U frequency among participants
in the SAPHIR study (Salzburg Atherosclerosis Prevention
Program, as previously published [14,20]). The frequencies of
Table 4. Frequencies of control region polymorphisms greater than 5% in either the control or cancer cohort.
Polymorphism in mtDNA
control region
Frequency in Control
Cohort (%) n
1
Frequency in Cancer
Cohort (%) n
1 P-Value
2 Odds Ratio (95% CI
3)
T 16172 C 3.60 10 5.26 16 0.331
T 16189 C 13.31 37 15.13 46 0.530
C 16192 T 5.76 16 6.58 20 0.680
C 16223 T 8.63 24 6.58 20 0.349
T 16224 C 7.55 21 9.54 29 0.393
C 16256 T 6.83 19 5.59 17 0.534
C 16270 T 9.35 26 8.88 27 0.844
C 16294 T 14.39 40 13.82 42 0.843
C 16296 T 8.63 24 5.26 16 0.108
T 16304 C 12.95 36 8.22 25 0.063
T 16311 C 18.71 52 17.11 52 0.615
T 16356 C 5.04 14 3.29 10 0.290
T 16362 C 11.51 32 7.57 23 0.104
T 16519 C 63.67 177 65.13 198 0.713
A 73 G 60.07 167 56.25 171 0.351
T 146 C 8.99 25 9.21 28 0.927
C 150 T 7.19 20 10.20 31 0.201
T 152 C 21.58 60 18.75 57 0.394
G 185 A 8.27 23 7.89 24 0.867
A 189 G 5.76 16 1.97 6 0.017 0.330 (0.127–0.855)
T 195 C 17.27 48 14.47 44 0.356
T 199 C 5.04 14 4.61 14 0.808
T 204 C 7.19 20 4.93 15 0.252
G 228 A 7.19 20 7.89 24 0.749
A 263 G 98.92 275 99.34 302 0.674
C 295 T 9.35 26 9.54 29 0.939
A 302 C-Ins 48.92 136 43.75 133 0.211
A 302 CC-Ins 13.31 37 13.49 41 0.950
T 310 C-Ins 97.12 270 99.34 302 0.054
C 462 T 8.63 24 9.21 28 0.807
T 489 C 11.15 31 9.87 30 0.614
C 497 T 2.88 8 5.92 18 0.076
G 499 A 5.04 14 3.29 10 0.290
G 513 CA-Ins 8.99 25 5.92 18 0.157
514/515 Del 8.99 25 4.93 15 0.053
1n=Number of individuals with the respective polymorphism.
2P-Value: Pearson chi-square or Fisher’s exact test.
3CI=Confidence interval.
doi:10.1371/journal.pone.0006370.t004
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significantly different from those of these healthy SAPHIR subjects.
A subgroup of this population, consisting only of men (n=988,
mean age 49 years), also has a frequency of haplogroup U similar to
the prostate cancer group (data not shown). Furthermore, the
frequency of haplogroup U among 277 random West European
Caucasiansstudied byBrandsta ¨tteretal.[21]alsoisnot significantly
different from the frequency in our control group (Table 5). The
subjects of that study were enrolled at the same University Hospital
in Austria where our patient and control cohorts were recruted.
In mtDNA-related epidemiological studies the importance of
appropriate control groups has been emphasized previously
[22,23]. There are several reasons that might explain the
discrepant results. For example, regional variation, age or sex
differences could influence the outcome of statistical calculations.
Booker et al. [18] do not define whether their control population
consisted entirely of men or also included women. Their control
cohort consisted of organ donors, who in the United States must
explicitly state their wish to become an organ donor; thus,
depending on the propensities of different ethnic groups to donate
organs, organ donor banks might exhibit different haplogroup
distributions compared to the general population. The mean age
of their controls was less than that of the patients with cancer. Age
could have an impact on regional population variation, especially
in a country such as the United States with a large immigrant
population. Immigration patterns might have changed over a
period of time, leading to different haplogroup distributions in
different age groups of a population.
In another US study which sought to replicate the findings of
Bookeretal.[18] with respecttoanassociationbetweenhaplogroup
U and prostate cancer in white men, Canter et al. [24] reported
haplogroup U percentages of 26.7% for their prostate cancer group
(n=71) and 11.7% for their control group (n=128). A limitation of
their study is the low number of prostate cancer patients. Moreover,
their brief report does not give characteristics of the study
participants or how they were selected.
It can not be excluded that geographical variation of haplogroup
frequencies in control study populations are present between
Austria and the USA.
In accordance with our results, a Korean study found no
association between any mitochondrial haplogroups and prostate
cancer [25]. The common set of 22 East Asian haplogroups was
examined and no statistically significant difference in the distribu-
tions of mtDNA haplogroup frequencies was observed between the
case (n=139) and control groups (n=122).
Comparing CR polymorphisms of cancer patients to controls
we found two out of 219 statistically significant differences, which
lost their significance after correction for multiple comparisons.
As we analyzed only mitochondrial haplogroups and control
region polymorphisms, we cannot exclude the possibility that
polymorphisms in the mitochondrial coding region, not included
in the predefined haplogroup polymorphisms, could be associated
with prostate cancer. Another limitation of our analysis is the low
study power. Very large sample sizes would be required to reliably
detect a modest difference in haplogroup frequencies between two
groups [26].
Somatic mutations of mtDNA have been reported in a variety of
cancers, including prostate carcinoma [27,28]. In this study, only
blood genomic DNA samples were available to us, and therefore
no associations between somatic mutations/polymorphisms could
be determined.
In conclusion, we did not find any mitochondrial haplogroups
or CR polymorphisms to be associated with prostate cancer in an
Austrian population.
Materials and Methods
Ethics Statement
The study was conducted according to the Austrian Gene
Technology Act and complied with the Declaration of Helsinki.
The study and the use of archive samples for the study was
approved by the Ethics Committee of the Innsbruck Medical
University (study UN 3174). Samples archived in 1995 to 2006
were used for the study. Written informed consent was obtained
starting in 2001.
Patients and control subjects
A total of 582 Caucasian subjects were analyzed; all were
recruited from the Department of Urology of the Innsbruck
Medical University. Patients and controls were enrolled in the
Tyrolean early detection program for prostate cancer, which is
based on regular PSA (prostate specific antigen) testing [29,30].
The case group comprises 304 men aged 51 to 84 years, diagnosed
with prostate cancer by histopathological evaluation according to
World Health Organisation recommendations. As a disease
control group, 278 men aged 46 to 80 years with benign results
of prostate biopsy were recruited as previously described [29]
(Table 1). For the disease control group a mean follow-up of 4.3
years after biopsy is available ranging from zero to 12 years, where
no cancer was diagnosed.
Table 5. Comparison of haplogroup U frequencies and important characteristics in different mitochondrial haplogroup studies.
Haplogroup U % P-Value
1 Mean (SD
2) age % male
Patients with benign changes (current study) n=278 16.9 - 66.1 (5.5) 100
Patients with prostate carcinoma (current study) n=304 16.1 0.798 70.3 (5.4) 100
Salzburg Atherosclerosis Prevention Program (SAPHIR), healthy subjects
(Wiesbauer et al., [20])
n=1527 15.5 0.540 51.5 (6.1) 64.7
Population study of West European Caucasians of the same geographical region
(random sample) (Brandsta ¨tter et al., [21])
n=277 18.8 0.566 n.a. n.a.
Patients with prostate carcinoma (Booker et al., [18]) n=221 16.7 0.961 56.7 (8.5) 100
Control population (Booker et al., [18]) n=246 9.3 0.011 34.2 (16.6) n.a.
1P-Values shown represent the comparison of haplogroup U frequencies between the control population of the present study and the other listed cohorts (Pearson chi-
square statistics).
2SD: Standard deviation; n.a.: not available.
doi:10.1371/journal.pone.0006370.t005
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DNA was isolated from frozen peripheral blood mononuclear
cells (PBMCs) using the AllPrep DNA/RNA Mini Kit 50 (Qiagen,
Hilden, Germany). A hierarchical system for mtDNA haplogroup-
ing that combines multiplex PCR amplification, multiplex single-
base primer extension, and capillary-based electrophoretic sepa-
ration for analyzing ten haplogroup-diagnostic mitochondrial
SNPs (mtSNPs) was used to determine the haplogroup distribution
of the most common European haplogroups, H, U, J, T, K, I, V,
W and X, as described previously [20].
However, the following changes were made to this protocol: To
remove primers and unincorporated deoxynucleotides from the PCR
products, an ExoSAP-IT (USB, Cleveland, OH, USA) digest in a
volume of 4.5 ml containing 0.5 mlE x o S A Pa n d2ml PCR product
was performed at 37uC for 60 min followed by enzyme inactivation
at 80uC for 15 min. Multiplex primer extension reactions were
carried out in a total volume of 5 ml containing 1 mlo fS N PS t a r t
Master Mix (GenomeLab
TM SNP Start Primer Extension Kit,
Beckman Coulter, Fullerton, CA, USA), 1 ml of PCR product, and
1 ml of primer mix. Two SNP primers were changed to 8251r:
(A)15GAGGGGGTGCTATAGGGTAAATACGGG and 16391r:
(A)6TGATTTCACGGAGGATGGTGGTCAAGGGA. As an in-
ternal standard, fluorescently labeled primers (Biomers, Ulm,
Germany) of lengths 15 and 60 bases were used (15 bases standard
DY781: CACATGTCGGAGTCT, 60 bases standard DY781:
TACAGTTCGTGCACACCGGCATCAGCTGTGTGCGAGA-
GTACTTACTATTGGTTGGCCAGA).
Haplogroups that could not be assigned to one of the nine major
European haplogroups by the SNP combination were designated
as ‘‘others’’.
CR sequences were analyzed between nucleotide positions
16145 and 530, from a 1066-bp fragment. The fragment was
amplified with primers 16098f: ACATTACTGCCAGCCAC-
CATG and 638r: GGTGATGTGAGCCCGTCTAAAC. The
PCR was performed in a volume of 30 ml containing 106 PCR
buffer B (Solis Biodyne, Tartu, Estonia), 2.5 mM MgCl2,
333.3 pM of forward and reverse primer, 133.3 mM of each
deoxynucleotide triphosphate (Invitrogen, Carlsbad, CA, USA)
and 0.083 U of Hot Fire Polymerase (Solis Biodyne, Tartu,
Estonia). Thermal cycling conditions were 95uC for 15 minutes, 35
cycles at 95uC for 30 seconds, 58uC for 30 seconds and 72uC for 2
minutes, and finally 37uC for 2 minutes.
PCR products were purified the same way as described for
haplogroup analysis (ExoSAP-IT, USB, Cleveland, OH, USA).
The fragment was sequenced using primers 16098f: ACAT-
TACTGCCAGCCACCATG and 17f: CCCTATTAACCACT-
CACGGG. Sequencing was conducted using GenomeLab
TM
DTCS – Quick Start Kit (Beckman Coulter, Fullerton, CA, USA)
in a volume of 10 ml containing 2 ml of the Master Mix and
500 pM of the appropriate primer. Thermal cycling conditions for
sequencing were performed with: 30 cycles of denaturation at
96uC for 5 seconds, annealing at 50uC for 5 seconds and extension
at 60uC for 4 minutes, followed by 25uC for 10 seconds. Samples
were ethanol-precipitated and separated by capillary electropho-
resis on a Beckman Coulter CEQ
TM 2000 Genetic Analysis
System.
Statistical analysis
Frequencies of all mitochondrial haplogroups and CR poly-
morphisms in the prostate cancer patients and controls were tested
for independency using Pearson chi-square statistics and Fisher’s
exact test as appropriate. Furthermore, in the same way,
frequencies of mitochondrial haplogroups in patients with prostate
carcinoma and biopsy Gleason Score #6 and patients with
prostate carcinoma and biopsy Gleason Score $7 were tested. A
p-value,0.05 was considered statistically significant. For analysis
of CR polymorphisms significant p-values were corrected for
multiple comparisons by Bonferroni analysis (required significance
level=0.05/number of comparisons), leading to a new required
significance level of ,0.00023 [number of comparisons=219]. All
analyses were performed using SPSS 15.0 student version (SPSS
GmbH Software, 80339 Munich, Germany).
Supporting Information
Table S1 Control region polymorphisms.
Found at: doi:10.1371/journal.pone.0006370.s001 (0.21 MB
DOC)
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